celecoxib · Scilex Pharms · NDA 212157
Elyxyb
Earliest generic entry, as listed
27 May 2036
Blocked by patent: US 10376527, US 10722456, US 10799517, US 9572819, US 9795620, US 9949990.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10376527 | product, use U-2718 | 27 May 2036 |
| US 10722456 | product, use U-2718 | 27 May 2036 |
| US 10799517 | product, use U-2718 | 27 May 2036 |
| US 9572819 | product, use U-2718 | 27 May 2036 |
| US 9795620 | product, use U-2718 | 27 May 2036 |
| US 9949990 | product, use U-2718 | 27 May 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212157 · 001 · RLD | solution, oral | 25MG/ML | 27 May 2036 |